3 days popular7 days popular1 month popular3 months popular

NIH launches large clinical trials of antibody-based HIV prevention

Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the AMP Studies, for antibody-mediated prevention, the trials will test whether giving people an investigational anti-HIV antibody called VRC01 as an intravenous infusion every 8 weeks is safe, tolerable and effective at preventing HIV infection. With a projected enrollment of 4,200 adults, the trials also are designed to answer fundamental scientific questions for the fields of HIV prevention and vaccine research.

VRC01 Antibody
This is a model of the VRC01 antibody.
Credit: NIAID